Treatment of astrocytomas
暂无分享,去创建一个
[1] E. Alexander,et al. Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. , 1989, International journal of radiation oncology, biology, physics.
[2] P. Kleihues,et al. Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. , 1988, Journal of neurosurgery.
[3] D P Byar,et al. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. , 1980, The New England journal of medicine.
[4] R. Mirimanoff,et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.
[5] Allan H Friedman,et al. Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] K. Sepkowitz,et al. Selective CD4+ lymphopenia in melanoma patients treated with temozolomide: a toxicity with therapeutic implications. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] P. Graham. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[8] Paul S Mischel,et al. Identification of molecular subtypes of glioblastoma by gene expression profiling , 2003, Oncogene.
[9] D F Nelson,et al. Combined modality approach to treatment of malignant gliomas--re-evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and the Eastern Cooperative Oncology Group. , 1988, NCI monographs : a publication of the National Cancer Institute.
[10] D. Louis,et al. Genetic analyses for predictors of radiation response in glioblastoma. , 2005, International journal of radiation oncology, biology, physics.
[11] A. Tolcher,et al. Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules , 2003, British Journal of Cancer.
[12] K. Hess,et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] D. Osoba,et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse , 2000, British Journal of Cancer.
[14] S. Ashley,et al. Modifying radical radiotherapy in high grade gliomas; shortening the treatment time through acceleration. , 1999, International journal of radiation oncology, biology, physics.
[15] Maria Werner-Wasik,et al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. , 2004, International journal of radiation oncology, biology, physics.
[16] Scar,et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. , 2000, The New England journal of medicine.
[17] J. Herman,et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.
[18] A. Arance,et al. O6‐methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: Results of a phase II study , 2000, International journal of cancer.
[19] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[20] S. Horvath,et al. Gene Expression Profiling of Gliomas Strongly Predicts Survival , 2004, Cancer Research.
[21] Susan M. Chang,et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] C. James,et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. , 2001, Journal of the National Cancer Institute.
[23] David M. Thomas,et al. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: a Medical Research Council trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] H. Bartelink,et al. European Organization for Research on Treatment of Cancer trials using radiotherapy with multiple fractions per day. A 1978-1987 survey. , 1988, Frontiers of radiation therapy and oncology.
[25] H. Fine,et al. Meta‐analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults , 1993, Cancer.
[26] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[27] M. Huncharek. Meta-analytic re-evaluation of misonidazole in the treatment of high grade astrocytoma. , 1998, Anticancer research.
[28] K. Aldape,et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. , 2005, Cancer research.
[29] E. Alexander,et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. , 1978, Journal of neurosurgery.
[30] D. Nelson,et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. , 1993, Journal of the National Cancer Institute.
[31] P. Steinbok,et al. Superfractionated radiotherapy in grade III, IV intracranial gliomas. , 1988, International journal of radiation oncology, biology, physics.
[32] R. Stupp,et al. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Temozolomide in Malignant Glioma Patients , 2004, Clinical Cancer Research.
[33] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] J. Haaga,et al. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. , 2001, Clinical Cancer Research.
[35] D P Byar,et al. Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. , 1983, Cancer treatment reports.
[36] R. McLendon,et al. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] R. Mirimanoff,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[38] D. Crowther,et al. Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. , 1994, British Journal of Cancer.
[39] M. Bernstein,et al. Randomized study of brachytherapy in the initial management of patients with malignant astrocytoma. , 1998, International journal of radiation oncology, biology, physics.
[40] J. Olson,et al. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy. , 2002, Neuro-oncology.
[41] W. Simpson,et al. Malignant astrocytoma. Hyperfractionated and standard radiotherapy with chemotherapy in a randomized prospective clinical trial , 1982, Cancer.
[42] T. Golub,et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.
[43] J. Jiricny,et al. Involvement of the mismatch repair system in temozolomide-induced apoptosis. , 1998, Molecular pharmacology.
[44] Z L Gokaslan,et al. Limitations of stereotactic biopsy in the initial management of gliomas. , 2001, Neuro-oncology.
[45] L. Stewart,et al. Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials , 2002, The Lancet.
[46] W. Curran,et al. Validation and predictive power of Radiation Therapy Oncology Group (RTOG) recursive partitioning analysis classes for malignant glioma patients: a report using RTOG 90-06. , 1998, International journal of radiation oncology, biology, physics.
[47] M. Ranson,et al. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] M. Prados,et al. A phase 3 randomized study of radiotherapy plus procarbazine, CCNU, and vincristine (PCV) with or without BUdR for the treatment of anaplastic astrocytoma: a preliminary report of RTOG 9404. , 1999, International journal of radiation oncology, biology, physics.
[49] I. Ferrer,et al. Prognostic Significance of O6-Methylguanine-DNA Methyltransferase Determined by Promoter Hypermethylation and Immunohistochemical Expression in Anaplastic Gliomas , 2005, Clinical Cancer Research.
[50] R. McLendon,et al. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[51] P. Ohneseit,et al. Loss of heterozygosity at 11p15 and p53 alterations in malignant gliomas , 2001, Journal of Cancer Research and Clinical Oncology.